Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 4 | EJNMMI Radiopharmacy and Chemistry

Fig. 4

From: [225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

Fig. 4

a DNA DSBs visualized by immunofluorescence microscopy probing for γ-H2AX foci in the nucleus of SK-BR-3 cells treated in vitro with medium, DOTA-trastuzumab or [225Ac]Ac-DOTA-trastuzumab at increasing specific activity (SA = 0.148–1.665 kBq/µg) or [225Ac]Ac-DOTA-trastuzumab (SA-1.665 kBq/µg) combined with a 100-fold excess of DOTA-trastuzumab to block HER2. b Integrated density of γ-H2AX foci in the nucleus of SK-BR-3 cells receiving these treatments. Significant differences are noted by the asterisks (*P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001). c. Correlation between the integrated density of γ-H2AX foci in the nucleus of SK-BR-3 cells versus absorbed dose deposited in the cells by [225Ac]Ac-DOTA-trastuzumab

Back to article page